Does the media favor IDYA or FTH?

In the previous week, IDEAYA Biosciences and IDEAYA Biosciences both had 5 articles in the media. IDEAYA Biosciences' average media sentiment score of 0.67 beat Sensei Biotherapeutics' score of 0.52 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VCYT or FTH?

In the previous week, Veracyte had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 6 mentions for Veracyte and 5 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.52 beat Veracyte's score of 0.39 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RCUS or FTH?

In the previous week, Arcus Biosciences and Arcus Biosciences both had 5 articles in the media. Sensei Biotherapeutics' average media sentiment score of 0.52 beat Arcus Biosciences' score of 0.06 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Sensei Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is DNLI or FTH more profitable?

Denali Therapeutics' return on equity of -55.27% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -55.27% -44.24% Sensei Biotherapeutics N/A -1,012.17% -175.69%

Does the media favor DNLI or FTH?

In the previous week, Denali Therapeutics and Denali Therapeutics both had 5 articles in the media. Denali Therapeutics' average media sentiment score of 0.88 beat Sensei Biotherapeutics' score of 0.52 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, FTH or DYN?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sensei Biotherapeutics N/A N/A -$21.08M -$141.65 N/A Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A

Is FTH or DYN more profitable?

Dyne Therapeutics' return on equity of -64.30% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -1,012.17% -175.69% Dyne Therapeutics N/A -64.30% -50.33%

Does the media refer more to FTH or DYN?

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than Dyne Therapeutics. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.18 beat Sensei Biotherapeutics' score of 0.52 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sensei Biotherapeutics (FTH) Competitors

$28.00 -1.05 (-3.61%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$27.30 -0.70 (-2.50%)

As of 09/25/2026 07:30 PM Eastern

Compare

FTH vs. IDYA, VCYT, RCUS, DNLI, and DYN

Should you buy Sensei Biotherapeutics stock or one of its competitors? Sensei Biotherapeutics's main competitors and comparable companies include IDEAYA Biosciences (IDYA), Veracyte (VCYT), Arcus Biosciences (RCUS), Denali Therapeutics (DNLI), and Dyne Therapeutics (DYN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sensei Biotherapeutics compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Sensei Biotherapeutics (NASDAQ:FTH) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

In the previous week, IDEAYA Biosciences and IDEAYA Biosciences both had 5 articles in the media. IDEAYA Biosciences' average media sentiment score of 0.67 beat Sensei Biotherapeutics' score of 0.52 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Sensei Biotherapeutics has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

IDEAYA Biosciences currently has a consensus price target of $52.69, suggesting a potential upside of 43.61%. Sensei Biotherapeutics has a consensus price target of $56.25, suggesting a potential upside of 100.89%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

IDEAYA Biosciences has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.28, suggesting that its stock price is 128% less volatile than the broader market.

Sensei Biotherapeutics has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.74	-$113.70M	-$1.94	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Summary

IDEAYA Biosciences beats Sensei Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Sensei Biotherapeutics (NASDAQ:FTH) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

In the previous week, Veracyte had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 6 mentions for Veracyte and 5 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.52 beat Veracyte's score of 0.39 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Veracyte presently has a consensus price target of $55.78, suggesting a potential upside of 22.78%. Sensei Biotherapeutics has a consensus price target of $56.25, suggesting a potential upside of 100.89%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

Veracyte has a net margin of 20.37% compared to Sensei Biotherapeutics' net margin of 0.00%. Veracyte's return on equity of 9.26% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

Veracyte has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.28, indicating that its share price is 128% less volatile than the broader market.

10.5% of Sensei Biotherapeutics shares are held by institutional investors. 1.6% of Veracyte shares are held by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Veracyte has higher revenue and earnings than Sensei Biotherapeutics. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	7.06	$66.35M	$1.41	32.22
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Summary

Veracyte beats Sensei Biotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Sensei Biotherapeutics (NASDAQ:FTH) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Sensei Biotherapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Arcus Biosciences' return on equity of -89.54% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

Sensei Biotherapeutics has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.84	-$353M	-$3.90	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Arcus Biosciences has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market.

Arcus Biosciences currently has a consensus target price of $38.30, suggesting a potential upside of 53.71%. Sensei Biotherapeutics has a consensus target price of $56.25, suggesting a potential upside of 100.89%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Arcus Biosciences and Arcus Biosciences both had 5 articles in the media. Sensei Biotherapeutics' average media sentiment score of 0.52 beat Arcus Biosciences' score of 0.06 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sensei Biotherapeutics beats Arcus Biosciences on 8 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Sensei Biotherapeutics (NASDAQ:FTH) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Denali Therapeutics currently has a consensus price target of $35.85, indicating a potential upside of 75.80%. Sensei Biotherapeutics has a consensus price target of $56.25, indicating a potential upside of 100.89%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

Denali Therapeutics' return on equity of -55.27% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

Sensei Biotherapeutics has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.86	-$512.54M	-$2.84	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

In the previous week, Denali Therapeutics and Denali Therapeutics both had 5 articles in the media. Denali Therapeutics' average media sentiment score of 0.88 beat Sensei Biotherapeutics' score of 0.52 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.28, meaning that its stock price is 128% less volatile than the broader market.

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Denali Therapeutics beats Sensei Biotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Dyne Therapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Sensei Biotherapeutics presently has a consensus target price of $56.25, suggesting a potential upside of 100.89%. Dyne Therapeutics has a consensus target price of $32.17, suggesting a potential upside of 100.67%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Sensei Biotherapeutics is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than Dyne Therapeutics. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.18 beat Sensei Biotherapeutics' score of 0.52 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sensei Biotherapeutics has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dyne Therapeutics' return on equity of -64.30% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
Dyne Therapeutics	N/A	-64.30%	-50.33%

Summary

Dyne Therapeutics beats Sensei Biotherapeutics on 7 of the 12 factors compared between the two stocks.

Get Sensei Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTH vs. The Competition

Export

Metric	Sensei Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$723.53M	$3.94B	$7.35B	$13.18B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	-0.20	14.15	275.82	25.76
Price / Sales	N/A	1,324.11	617.28	84.78
Price / Cash	N/A	40.88	28.02	35.00
Price / Book	1.90	15.32	10.48	6.36
Net Income	-$21.08M	-$22.83M	$3.51B	$360.40M
7 Day Performance	-18.84%	-2.94%	-1.31%	-0.23%
1 Month Performance	-17.01%	-8.80%	-4.61%	-4.16%
1 Year Performance	N/A	28.99%	15.01%	4.58%

Sensei Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTH Sensei Biotherapeutics	3.5098 of 5 stars	$28.00 -3.6%	$56.25 +100.9%	N/A	$723.53M	N/A	N/A	29	News Coverage Analyst Downgrade
IDYA IDEAYA Biosciences	2.7822 of 5 stars	$39.71 +2.2%	$52.69 +32.7%	+36.7%	$3.41B	$218.71M	N/A	145	Analyst Forecast
VCYT Veracyte	4.2371 of 5 stars	$43.36 +4.4%	$55.78 +28.6%	+35.9%	$3.34B	$517.15M	30.75	755	Analyst Downgrade Insider Trade
RCUS Arcus Biosciences	2.8255 of 5 stars	$26.92 +3.7%	$38.30 +42.3%	+94.3%	$3.30B	$247M	N/A	601
DNLI Denali Therapeutics	3.1489 of 5 stars	$21.60 +5.5%	$35.85 +66.0%	+46.2%	$3.27B	$330.53M	N/A	507	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTH) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensei Biotherapeutics (FTH) Competitors

FTH vs. IDYA, VCYT, RCUS, DNLI, and DYN

How does Sensei Biotherapeutics compare to IDEAYA Biosciences?

Summary

How does Sensei Biotherapeutics compare to Veracyte?

Summary

How does Sensei Biotherapeutics compare to Arcus Biosciences?

Summary

How does Sensei Biotherapeutics compare to Denali Therapeutics?

Summary

How does Sensei Biotherapeutics compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensei Biotherapeutics (FTH) Competitors

FTH vs. IDYA, VCYT, RCUS, DNLI, and DYN

How does Sensei Biotherapeutics compare to IDEAYA Biosciences?

Does the media favor IDYA or FTH?

Is IDYA or FTH more profitable?

Do analysts recommend IDYA or FTH?

Do institutionals & insiders have more ownership in IDYA or FTH?

Which has more volatility & risk, IDYA or FTH?

Which has preferable earnings and valuation, IDYA or FTH?

Summary

How does Sensei Biotherapeutics compare to Veracyte?

Does the media favor VCYT or FTH?

Do analysts prefer VCYT or FTH?

Is VCYT or FTH more profitable?

Which has more volatility and risk, VCYT or FTH?

Do institutionals & insiders hold more shares of VCYT or FTH?

Which has preferable earnings and valuation, VCYT or FTH?

Summary

How does Sensei Biotherapeutics compare to Arcus Biosciences?

Is RCUS or FTH more profitable?

Which has better earnings and valuation, RCUS or FTH?

Which has more volatility & risk, RCUS or FTH?

Do analysts rate RCUS or FTH?

Do institutionals and insiders have more ownership in RCUS or FTH?

Does the media prefer RCUS or FTH?

Summary

How does Sensei Biotherapeutics compare to Denali Therapeutics?

Do analysts rate DNLI or FTH?

Is DNLI or FTH more profitable?

Which has stronger valuation and earnings, DNLI or FTH?

Does the media favor DNLI or FTH?

Which has more risk & volatility, DNLI or FTH?

Do institutionals and insiders believe in DNLI or FTH?

Summary

How does Sensei Biotherapeutics compare to Dyne Therapeutics?

Do analysts prefer FTH or DYN?

Which has better valuation and earnings, FTH or DYN?

Does the media refer more to FTH or DYN?

Which has more volatility and risk, FTH or DYN?

Do institutionals & insiders hold more shares of FTH or DYN?

Is FTH or DYN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools